Novo Nordisk set to launch weight loss drugs in more countries but in constrained fashion, CEO says

It’s been well documented how Novo Nordisk has had difficulty in meeting the soaring demand for its GLP-1 weight loss treatments. But on Friday, CEO Lars Fruergaard Jørgensen said the Danish company plans to launch in “more and more” countries.